What's Happening?
A recent nationwide nested case-control study published in BMJ has linked oral menopausal hormone therapy (MHT) to an increased risk of thrombotic events, including venous thromboembolism (VTE), ischemic stroke, and myocardial infarction (MI). The study found
that high-dose oral estradiol (more than 1 mg daily) carried a higher risk for VTE (HR 1.8), ischemic stroke (HR 1.5), and MI (HR 1.4). Low-dose oral therapy (1 mg or less daily) also showed an increased VTE risk (HR 1.3) but no significant increase for stroke or MI. The risk for VTE was highest during the first year of high-dose oral therapy. In contrast, transdermal therapy was not associated with higher rates of VTE, ischemic stroke, or MI, with the exception of MI with transdermal combined cyclic therapy, which was based on sparse data. The study's authors noted limitations, including its observational nature and lack of data on BMI, smoking status, and age at menopause onset.
Why It's Important?
This study is important for U.S. healthcare providers and women considering or currently using MHT, as it provides contemporary data on the risks associated with different formulations and dosages. The findings challenge the notion that all MHT is uniformly safe or unsafe, emphasizing that risk can vary significantly based on the type, dose, and duration of treatment. The distinction between oral and transdermal therapies is particularly critical, suggesting that transdermal options may carry a lower thrombotic risk. This information can help clinicians make more informed decisions when prescribing MHT, tailoring treatments to individual patient profiles and risk factors. It also highlights the ongoing need for personalized medicine in menopause management, moving beyond generalized recommendations to consider individual patient characteristics.
What's Next?
The study's co-author, Amani Meaidi, MD, PhD, emphasized that the safety question regarding MHT remains open and called for further research to understand individual differences in response to therapy. Key unanswered questions include identifying who is most likely to benefit from MHT, for whom the balance of benefits and harms is less favorable, and how age, comorbidities, and baseline risk modify these effects. This suggests a future direction for research focused on personalized medicine in menopause management. The findings may also prompt a re-evaluation of clinical guidelines and patient counseling regarding MHT, particularly concerning the choice between oral and transdermal routes and appropriate dosing strategies. The FDA's 2025 decision to remove the boxed warning from hormone therapy products is also brought into question by these findings, suggesting a need for continued vigilance and updated risk communication.
Beyond the Headlines
The debate surrounding the safety and efficacy of menopausal hormone therapy has a complex history, marked by shifting medical recommendations and public perception. The initial enthusiasm for MHT was tempered by concerns about cardiovascular risks, leading to a significant decline in its use. This new study contributes to the ongoing re-evaluation, suggesting that while risks exist, they are not uniform across all formulations. The emphasis on personalized medicine and the call for research into individual patient responses highlight a broader trend in healthcare towards more nuanced and patient-centered approaches. This evolution in understanding underscores the importance of continuous research and critical assessment of medical interventions, ensuring that clinical practices are based on the most current and comprehensive evidence available.
